^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    REGN6569

    i
    Other names: REGN6569, REGN 6569, REGN-6569
    Associations

    News

    Trials
    Company:
    Regeneron
    Drug class:
    GITR agonist
    Related drugs:
    Associations

    News

    Trials
    10ms
    Study of REGN6569 and Cemiplimab in Adult Patients With Advanced Solid Tumor Malignancies (clinicaltrials.gov)
    P1, N=38, Terminated, Regeneron Pharmaceuticals | Trial completion date: Sep 2025 --> Feb 2025 | Active, not recruiting --> Terminated; Sponsor Decision
    Trial completion date • Trial termination
    |
    TNFA (Tumor Necrosis Factor-Alpha)
    |
    Libtayo (cemiplimab-rwlc) • REGN6569
    1year
    Study of REGN6569 and Cemiplimab in Adult Patients With Advanced Solid Tumor Malignancies (clinicaltrials.gov)
    P1, N=38, Active, not recruiting, Regeneron Pharmaceuticals | Recruiting --> Active, not recruiting | N=85 --> 38 | Trial completion date: Jun 2026 --> Sep 2025
    Enrollment closed • Enrollment change • Trial completion date • Metastases
    |
    TNFA (Tumor Necrosis Factor-Alpha)
    |
    Libtayo (cemiplimab-rwlc) • REGN6569
    almost2years
    Study of REGN6569 and Cemiplimab in Adult Patients With Advanced Solid Tumor Malignancies (clinicaltrials.gov)
    P1, N=85, Recruiting, Regeneron Pharmaceuticals | Active, not recruiting --> Recruiting | Trial primary completion date: Jul 2026 --> Apr 2025
    Enrollment open • Trial primary completion date • Metastases
    |
    TNFA (Tumor Necrosis Factor-Alpha)
    |
    Libtayo (cemiplimab-rwlc) • REGN6569
    over2years
    Study of REGN6569 and Cemiplimab in Adult Patients With Advanced Solid Tumor Malignancies (clinicaltrials.gov)
    P1, N=85, Active, not recruiting, Regeneron Pharmaceuticals | Recruiting --> Active, not recruiting
    Enrollment closed • Metastases
    |
    TNFA (Tumor Necrosis Factor-Alpha)
    |
    Libtayo (cemiplimab-rwlc) • REGN6569
    over4years
    Study of REGN6569 and Cemiplimab in Adult Patients With Advanced Solid Tumor Malignancies (clinicaltrials.gov)
    P1, N=85, Recruiting, Regeneron Pharmaceuticals | Suspended --> Recruiting | Trial completion date: Oct 2025 --> Jun 2026 | Trial primary completion date: Oct 2025 --> Jun 2026
    Clinical • Enrollment open • Trial completion date • Trial primary completion date
    |
    TNFA (Tumor Necrosis Factor-Alpha)
    |
    Libtayo (cemiplimab-rwlc) • REGN6569
    almost5years
    Study of REGN6569 and Cemiplimab in Adult Patients With Advanced Solid Tumor Malignancies (clinicaltrials.gov)
    P1, N=75, Suspended, Regeneron Pharmaceuticals | Recruiting --> Suspended
    Clinical • Trial suspension
    |
    TNFA (Tumor Necrosis Factor-Alpha)
    |
    Libtayo (cemiplimab-rwlc) • REGN6569
    5years
    Study of REGN6569 and Cemiplimab in Adult Patients With Advanced Solid Tumor Malignancies (clinicaltrials.gov)
    P1, N=75, Recruiting, Regeneron Pharmaceuticals | Not yet recruiting --> Recruiting
    Clinical • Enrollment open
    |
    TNFA (Tumor Necrosis Factor-Alpha)
    |
    Libtayo (cemiplimab-rwlc) • REGN6569